LONG
BEACH, Calif., June 4, 2024
/PRNewswire/ -- Single Pass and Mermaid Medical have confirmed that
four patients were successfully treated with the Kronos Biopsy
Closure device at MemorialCare Long Beach Medical Center.
The two liver and two kidney biopsy procedures were performed by
David Tahour, MD, DABR, Chief of
Interventional Radiology, who confirmed the positive results.
Said Dr. Tahour "the device offers a breakthrough solution
for patients undergoing percutaneous biopsy who are at high risk of
bleeding complications. Knowing such a solution exists places
both patients and physicians at ease and will create
opportunities in the future for patients who might otherwise not
been a candidate for biopsy."
Bill Colone, CEO of Single Pass,
added "the clinical success we have seen thus far in Europe, and now in the US, confirms our
innovation value proposition of improving the safety of
needle-guided biopsy procedures for high-risk patients."
These cases, proctored by Dr. Tahour, also served as device
training for the Clinical Specialists from Mermaid Medical, the
Single Pass US national distribution partner.
The Kronos Biopsy Closure device is now commercially available
through both the CE Mark under EU MDR and US 510(k) clearance.
Media Contact:
Bill Colone
6026183377
378609@email4pr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/single-pass-and-mermaid-medical-announce-completion-of-the-first-kronos-biopsy-closure-device-procedures-in-the-us-post-fda-clearance-302163078.html
SOURCE Single Pass, Inc.